Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “buy” rating reaffirmed by investment analysts at Oppenheimer Holdings, Inc. in a research report issued on Thursday. They presently have a $70.00 target price on the stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 19.37% from the stock’s current price.

Several other research analysts also recently weighed in on NBIX. Bank of America Corporation reiterated a “buy” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a report on Monday, May 15th. Jefferies Group LLC reissued a “buy” rating and set a $67.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, May 22nd. Needham & Company LLC reissued a “buy” rating and set a $58.00 price objective (down from $62.00) on shares of Neurocrine Biosciences in a research note on Wednesday, May 24th. Leerink Swann lowered their price objective on shares of Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, May 25th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $75.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, May 25th. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $68.25.

Neurocrine Biosciences (NASDAQ NBIX) traded down 1.26% during midday trading on Thursday, reaching $57.90. 645,221 shares of the company traded hands. The firm has a 50-day moving average price of $52.12 and a 200-day moving average price of $48.30. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $60.00. The firm’s market capitalization is $5.11 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same period in the previous year, the business earned ($0.46) EPS. Equities analysts predict that Neurocrine Biosciences will post ($2.45) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/07/neurocrine-biosciences-nbix-buy-rating-reiterated-at-oppenheimer-holdings-inc.html.

In related news, insider Dimitri E. Grigoriadis sold 15,354 shares of the company’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $55.00, for a total transaction of $844,470.00. Following the completion of the sale, the insider now directly owns 123,045 shares of the company’s stock, valued at approximately $6,767,475. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total transaction of $436,700.00. Following the sale, the insider now directly owns 57,707 shares of the company’s stock, valued at $2,885,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,588 shares of company stock valued at $2,406,170. 4.80% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in NBIX. The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. First Mercantile Trust Co. boosted its position in Neurocrine Biosciences by 22.2% during the 1st quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after purchasing an additional 560 shares during the period. ARS Investment Partners LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter worth $207,000. Stephens Inc. AR purchased a new stake in Neurocrine Biosciences during the 2nd quarter worth $207,000. Finally, Capstone Asset Management Co. purchased a new stake in Neurocrine Biosciences during the 1st quarter worth $214,000.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.